Top Page
Invion
(OTC:IVX)
Invion (IVX) vs. S&P 500 (SPY)
Invion Business Overview & Revenue Model
Invion Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.47M | 3.69M | 4.10M | 3.29M | 2.33M | 3.48M | Gross Profit |
| -202.54K | 1.00M | 1.21M | 969.12K | 810.50K | 1.92M | EBIT |
| -7.64M | -5.44M | -1.65M | -2.32M | -1.57M | -1.03M | EBITDA |
| -5.97M | -4.57M | -965.37K | -1.90M | -1.29M | -748.56K | Net Income Common Stockholders |
| -6.79M | -5.63M | -1.61M | -2.24M | -1.48M | -953.89K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 736.45K | 783.53K | 4.08M | 8.47M | 1.04M | 618.84K | Total Assets |
| 13.85M | 15.45M | 19.05M | 20.04M | 5.64M | 5.76M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
| -736.45K | -783.53K | -4.08M | -8.47M | -1.04M | -618.84K | Total Liabilities |
| 722.06K | 1.01M | 650.63K | 462.41K | 851.50K | 326.82K | Stockholders Equity |
| 13.13M | 14.44M | 18.40M | 19.58M | 4.79M | 5.43M |
| Cash Flow | Free Cash Flow | ||||
| -2.78M | -3.30M | -4.39M | -8.36M | 417.98K | -152.47K | Operating Cash Flow |
| -2.78M | -2.40M | -1.81M | -1.11M | 417.98K | -152.47K | Investing Cash Flow |
| 0.00 | -900.00K | -2.58M | -7.25M | 0.00 | 0.00 | Financing Cash Flow |
| 1.58M | 0.00 | 15.80M | 15.80M | 0.00 | 0.00 |
Invion Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$216.29M | ― | -37.20% | ― | ― | 32.02% | |
52 Neutral | $5.15B | 3.56 | -42.52% | 2.83% | 14.56% | -0.50% | |
45 Neutral | $82.61M | ― | -55.44% | ― | ― | 49.25% | |
43 Neutral | AU$7.59M | ― | -44.03% | ― | -66.59% | -351.30% | |
37 Underperform | $164.27M | ― | -99.05% | ― | ― | -34.09% | |
36 Underperform | $3.98M | ― | -119.28% | ― | ― | 64.10% |
Invion Corporate Events
Invion Limited has successfully dosed the first six patients in its Phase I/II trial for non-melanoma skin cancer (NMSC) using its topical drug INV043. This milestone initiates a safety review by the Safety Review Committee, which will assess the need for adjustments in the trial’s next stage. The trial, which evaluates the safety and efficacy of INV043, aims to provide an effective alternative to surgery, potentially reducing scarring and pain. The global market for NMSC treatment is projected to reach $21.1 billion by 2032, highlighting the significance of Invion’s advancements in this field.
Invion Limited has made significant progress in its clinical programs for Photosoft technology, including advancing its Phase I/II skin cancer trial by opening a second clinical site and completing dosing of five patients. The company has also expanded its collaboration with Hanlim Pharm to include oesophageal cancer, a market projected to grow significantly. Additionally, Invion secured $2 million through a share placement to accelerate its clinical programs, with the first tranche of funds already received. The company’s Photosoft technology was featured at Stanford Medicine’s Lung Cancer Summit, highlighting its innovative approach in cancer treatment.
Invion Limited has announced that it will hold its Extraordinary General Meeting (EGM) virtually on May 9, 2025. The meeting will allow shareholders to participate and vote in real-time, ensuring accessibility and engagement. This virtual format aligns with recent legislative changes and reflects Invion’s commitment to modernizing shareholder interactions. The company encourages shareholders to submit questions in advance and to register for the meeting online, emphasizing the importance of proxy voting.
Invion Limited has issued 87,273 fully paid ordinary shares at no cost per share, as part of its compliance with the Corporations Act. The company is in preliminary discussions with RMW Cho Group Limited to potentially expand its rights to the Photosoft™ technology to new territories or indications. These discussions are still in early stages, and there is no guarantee of a binding agreement. This move could impact Invion’s operational scope and market positioning if successful.
Invion Limited has issued over 7 million new shares at $0.14 each, under a Tranche 1 Placement, without disclosure to investors as per the Corporations Act. The company is in preliminary talks with RMW Cho Group Limited to potentially expand its rights to Photosoft™ technology into new territories or indications, although no binding agreement has been reached yet.
Invion Limited has announced the quotation of 7,035,447 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of March 11, 2025. This move is part of a previously announced transaction and could potentially enhance the company’s financial flexibility and market presence, impacting its stakeholders and positioning within the biotechnology sector.
Invion Limited announced an update to its previous securities issuance, adjusting capacity calculations to utilize 6,641,068 shares from section 7.1A and 394,379 from section 7.1. This update reflects the company’s strategic financial maneuvering to optimize its market position and potentially enhance shareholder value.
Invion Limited has issued over two million fully paid ordinary shares, enhancing its financial position. The company is in preliminary discussions with RMW Cho Group Limited to potentially expand its Photosoft ™ technology rights to new territories or indications, though no binding agreement has been reached yet.
Invion Limited has announced the quotation of 2,118,645 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code IVX. This move is part of previously announced transactions and is expected to enhance the company’s market presence and liquidity, potentially benefiting stakeholders by increasing the company’s visibility and access to capital.
Invion Limited announced a proposed issue of securities, including unlisted options and ordinary fully paid shares, totaling 14,285,716 securities. This move is part of a placement or other type of issue, aimed at raising capital to support the company’s ongoing operations and strategic initiatives, potentially enhancing its market position and providing value to stakeholders.
Invion Limited has successfully completed a $2 million share placement to accelerate its clinical programs, including a Phase I/II trial for skin cancer and an anogenital trial in collaboration with the Peter MacCallum Cancer Centre. The funds will also support general working capital and potentially enable orphan drug designation in the US for the anogenital trial, offering a faster commercialization path for Photosoft™. The placement was met with strong demand, highlighting investor confidence in Invion’s strategic milestones, including updates on glioblastoma, oesophageal cancer, and HPV studies.
Invion Limited reported a significant increase in losses for the half-year ending December 31, 2024, with a 162.2% rise in losses attributable to owners, amounting to $1,872,230. The company experienced a complete drop in revenues from ordinary activities, and no dividends were paid or declared during this period, highlighting financial challenges.
Invion Limited has requested a trading halt on its securities on the Australian Securities Exchange pending an announcement regarding a capital raising initiative. This move is intended to help the company manage its continuous disclosure obligations, with the trading halt expected to last until the announcement is made or normal trading resumes on March 4, 2025. The outcome of this announcement could have significant implications for Invion’s financial strategy and market positioning.
Invion Limited has expanded its collaboration with South Korean pharmaceutical group Hanlim to include oesophageal cancer in its development program for the cancer drug candidate INV043. This partnership, which initially focused on glioblastoma, will see Hanlim funding studies while Invion retains rights to the Photosoft™ technology and any new intellectual property. The collaboration aims to address the high unmet need for oesophageal cancer treatments, leveraging Hanlim’s resources and expertise. The global market for oesophageal cancer is projected to grow significantly, enhancing Invion’s industry positioning and offering potential new therapeutic options for high-need cancers.